Securities Investigation on Behalf of Ascendis Pharma A/S Investors

Investors of Ascendis Pharma A/S Stock Who Have Suffered Losses of At Least $50,000 Encouraged to Contact Kehoe Law Firm, P.C. – ASND

Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Ascendis Pharma A/S (“Ascendis,” “Ascendis Pharma” or the “Company”) (NASDAQ: ASND).

INVESTORS OF ASCENDIS PHARMA STOCK WHO HAVE SUFFERED FINANCIAL LOSSES OF $50,000 OR MORE ARE ENCOURAGED TO CLICK HERE TO CONTACT KEHOE LAW FIRM, P.C. AND PROVIDE DETAILS OF THEIR ASCENDIS SECURITIES.

Investors should be aware that on April 3, 2023, Ascendis “. . . announced that the U.S. Food & Drug Administration (‘FDA’) has notified the Company that, as part of their ongoing review, the FDA has identified deficiencies in the Company’s New Drug Application (‘NDA’) for TransCon PTH (palopegteriparatide) in hypoparathyroidism that at this time precludes them from holding further discussions about labeling and post-marketing requirements/commitments. The deficiencies were not disclosed in the letter.”

ASCENDIS PHARMA SHAREHOLDERS WHO SUFFERED SIGNIFICANT LOSSES ARE ALSO ENCOURAGED TO CONTACT MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected], [email protected], TO LEARN MORE ABOUT THE INVESTIGATION OR POTENTIAL LEGAL CLAIMS.